A bit of good news amid the bad

Rhode Island continues to suffer from high unemployment and an unfulfilled quest for the better economy of the future.

Yet Neurotech is due to hold a ribbon-cutting in Cumberland tomorrow, and the company represents the sort of technological effort from which the state will benefit. Here's a description:

Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology. Neurotech’s lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigmentosa (RP), an inherited disease leading to blindness, and geographic atrophy, a serious condition associated with atrophic (dry) macular degeneration.